After the trading day commenced, OWCP released a sweet little 8-K that talked about their new research agreement with Medical Research Infrastructure Development and Health Services Fund by Chaim Sheba Medical Center, the largest hospital in Israel.

Now, let’s look back at the headline of PharmaBiz.com‘s November 17th article — “OWCP to seek Israeli IRB committee approval to conduct safety study of psoriasis topical cream”

OWCP, or research companies in general, need the IRB committee approval in order to conduct the research in which OWCP just announced in the 8-K.

This is a huge, positive step in the direction of success for OWCP’s psoriasis cream.

Will this news lead to $1/share by end of January?  Considering it’s still absolutely the opinion of many that OWCP is grossly undervalued even at $1/share ($140M Market Value) — we sure hope so! If the Market Value doesn’t start “correcting itself” over the next few months, we’re going to see a crazy surge in share price when the product does launch in Quarter 2 — in my opinion.